Patents by Inventor Hans-Peter Vornlocher

Hans-Peter Vornlocher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11078484
    Abstract: The present invention relates to methods of administering to a subject multimeric oligonucleotides having monomeric subunits joined by linkers. The multimeric oligonucleotides have a molecular weight of at least about 45 kD and other characteristics, such that their clearance due to glomerular filtration is reduced. The present invention also relates to such multimeric oligonucleotides and methods of synthesizing such multimeric oligonucleotides.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: August 3, 2021
    Assignee: MPEG LA, LLC
    Inventors: Jonathan Miles Brown, Kristin K. H. Neuman, Hans-Peter Vornlocher, Philipp Hadwiger
  • Publication number: 20210187007
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: December 9, 2020
    Publication date: June 24, 2021
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Saetrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
  • Publication number: 20210189393
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Application
    Filed: February 23, 2021
    Publication date: June 24, 2021
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Patent number: 10912790
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: February 9, 2021
    Assignee: MiNA THERAPEUTICS LIMITED
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Sætrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
  • Publication number: 20200376020
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: April 21, 2016
    Publication date: December 3, 2020
    Applicant: MiNA THERAPEUTICS LIMITED
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Sætrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
  • Publication number: 20200231968
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Application
    Filed: November 4, 2019
    Publication date: July 23, 2020
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Publication number: 20200157550
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 21, 2020
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, JR., Hans-Peter Vornlocher
  • Patent number: 10544418
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: January 28, 2020
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Patent number: 10501740
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: December 10, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Publication number: 20190264203
    Abstract: The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.
    Type: Application
    Filed: October 5, 2018
    Publication date: August 29, 2019
    Inventors: Andrea FORST, Philipp HADWIGER, Hans-Peter VORNLOCHER
  • Publication number: 20190085331
    Abstract: Defined multi-conjugate oligonucleotides can have predetermined sizes and compositions. For example, in various embodiment, defined multi-conjugate oligonucleotides can have advantageous properties, for example in the form of defined multi-conjugate siRNA (i.e., including two, three or more siRNA) having enhanced intracellular delivery and/or multi-gene silencing effects. In various embodiment, the defined multi-conjugate oligonucleotides can be synthesized via new synthetic intermediates and methods. The defined multi-conjugate oligonucleotides can be used, for example, in reducing gene expression, biological research, treating or preventing medical conditions, or to produce new or altered phenotypes in cells or organisms.
    Type: Application
    Filed: June 15, 2016
    Publication date: March 21, 2019
    Applicant: MPEG LA, LLC
    Inventors: Philipp Hadwiger, Hans-Peter Vornlocher, Jonathan Miles Brown, James Everett Dahlman, Kristin K. H. Neuman
  • Patent number: 10131907
    Abstract: The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: November 20, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Andrea Forst, Philipp Hadwiger, Hans-Peter Vornlocher
  • Publication number: 20180223284
    Abstract: The present invention relates to methods of administering to a subject multimeric oligonucleotides having monomeric subunits joined by linkers. The multimeric oligonucleotides have a molecular weight of at least about 45 kD and other characteristics, such that their clearance due to glomerular filtration is reduced. The present invention also relates to such multimeric oligonucleotides and methods of synthesizing such multimeric oligonucleotides.
    Type: Application
    Filed: February 6, 2018
    Publication date: August 9, 2018
    Inventors: Kristin K. H. Neuman, Jonathan Miles Brown, Hans-Peter Vornlocher
  • Publication number: 20180148726
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: January 18, 2018
    Publication date: May 31, 2018
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Publication number: 20180127749
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Application
    Filed: August 14, 2017
    Publication date: May 10, 2018
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Patent number: 9914927
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: March 13, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Publication number: 20170121709
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Application
    Filed: August 18, 2016
    Publication date: May 4, 2017
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Publication number: 20160376599
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: September 9, 2016
    Publication date: December 29, 2016
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Patent number: 9476052
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: October 25, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Patent number: 9441225
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: September 13, 2016
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, John M. Maraganore